|
|
|
| The gut microbiome and intestinal failure-associated liver disease |
| Lu Jiang a , b , c , Juan Xu a , Si-Yang Cheng d , Ying Wang a , c , Wei Cai a , b , c , d , ∗ |
a Division of Pediatric Gastroenterology and Nutrition, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China
b Shanghai Institute for Pediatric Research, Shanghai 200092, China
c Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition, Shanghai 200092, China
d Department of Pediatric Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China
∗Corresponding author at: Department of Pediatric Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.
E-mail addresses: caiw1978@163.com , caiw204@sjtu.edu.cn (W. Cai). |
|
|
|
|
Abstract Intestinal failure-associated liver disease (IFALD) is a common hepatobiliary complication resulting from long-term parenteral nutrition (PN) in patients with intestinal failure. The spectrum of IFALD ranges from cholestasis, steatosis, portal fibrosis, to cirrhosis. Development of IFALD is a multifactorial process, in which gut dysbiosis plays a critical role in its initiation and progression in conjunction with increased intestinal permeability, activation of hepatic immune responses, and administration of lipid emulsion. Gut microbiota manipulation including pre/probiotics, fecal microbiota transplantation, and antibiotics has been studied in IFALD with varying success. In this review, we summarize current knowledge on the taxonomic and functional changes of gut microbiota in preclinical and clinical studies of IFALD. We also review the function of microbial metabolites and associated signalings in the context of IFALD. By providing microbiota-targeted interventions aiming to optimize PN-induced liver injury, our review provides perspectives for future basic and translational investigations in the field.
|
|
|
|
|
|
|
|
|
2023, Vol. 22 
